Medasorb edges closer to EU sepsis market
This article was originally published in Clinica
Executive Summary
Medasorb is a step closer to the estimated $6bn European sepsis market, following approval to proceed with a European trial of its Cytosorb haemoperfusion device. If successful, the trial will support a CE mark application for the technology.